开云app官网登录入口网页版-官方正版

#纤维化间质性肺病#

6篇内容 | 922人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2218770, encodeId=1e8f2218e709e, content=<a href='/topic/show?id=4623e7235f9' target=_blank style='color:#2F92EE;'>#纤维化间质性肺病#</a>, objectTitle=European Radiology：CT定量在进行性纤维化间质性肺病中的价值, objectType=article, longId=837884, objectId=593b83e88434, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240711/1720691473105_92910.png, objectUrl=/article/show_article.do?id=593b83e88434, replyNumber=0, likeNumber=26, createdTime=2024-08-06, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=593b83e88434, moduleTitle=European Radiology：CT定量在进行性纤维化间质性肺病中的价值, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=593b83e88434)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2055017, encodeId=255f205501e0a, content=<a href='/topic/show?id=4623e7235f9' target=_blank style='color:#2F92EE;'>#纤维化间质性肺病#</a>, objectTitle=晚期肺结节病患者进行性纤维化间质性肺病表型的特征, objectType=article, longId=730567, objectId=a577e30567cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a577e30567cc, replyNumber=0, likeNumber=101, createdTime=2023-06-10, rootId=0, userName=654699882_84926986, userId=85df2500173, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a577e30567cc, moduleTitle=晚期肺结节病患者进行性纤维化间质性肺病表型的特征, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=a577e30567cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2055015, encodeId=e56c2055015d9, content=<a href='/topic/show?id=4623e7235f9' target=_blank style='color:#2F92EE;'>#纤维化间质性肺病#</a>, objectTitle=Front Med：进行性纤维化间质性肺病 (PF-ILD) 的管理, objectType=article, longId=219999, objectId=74db219999ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=74db219999ed, replyNumber=0, likeNumber=76, createdTime=2022-06-07, rootId=0, userName=654699882_84926986, userId=85df2500173, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=74db219999ed, moduleTitle=Front Med：进行性纤维化间质性肺病 (PF-ILD) 的管理, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=74db219999ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2055016, encodeId=b96b205501623, content=<a href='/topic/show?id=4623e7235f9' target=_blank style='color:#2F92EE;'>#纤维化间质性肺病#</a>, objectTitle=Chest：纤维化间质性肺病患者体重指数和体重变化与死亡率之间的相关性, objectType=article, longId=220806, objectId=f29a2208061b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f29a2208061b, replyNumber=0, likeNumber=75, createdTime=2022-10-27, rootId=0, userName=654699882_84926986, userId=85df2500173, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f29a2208061b, moduleTitle=Chest：纤维化间质性肺病患者体重指数和体重变化与死亡率之间的相关性, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=f29a2208061b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2055012, encodeId=dfea2055012fd, content=<a href='/topic/show?id=4623e7235f9' target=_blank style='color:#2F92EE;'>#纤维化间质性肺病#</a>, objectTitle=2019年ERS：Nintedanib减慢纤维化间质性肺病的进展, objectType=article, longId=180637, objectId=7ff718063eac, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7ff718063eac, replyNumber=0, likeNumber=80, createdTime=2020-03-31, rootId=0, userName=654699882_84926986, userId=85df2500173, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7ff718063eac, moduleTitle=2019年ERS：Nintedanib减慢纤维化间质性肺病的进展, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=7ff718063eac)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2055014, encodeId=d6ed205501437, content=<a href='/topic/show?id=4623e7235f9' target=_blank style='color:#2F92EE;'>#纤维化间质性肺病#</a>, objectTitle=FDA扩展了勃林格殷格翰的尼达尼布的适应症，用于治疗具有进展表型的慢性纤维化间质性肺病, objectType=article, longId=189668, objectId=1f7f18966870, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1f7f18966870, replyNumber=0, likeNumber=71, createdTime=2020-10-08, rootId=0, userName=654699882_84926986, userId=85df2500173, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1f7f18966870, moduleTitle=FDA扩展了勃林格殷格翰的尼达尼布的适应症，用于治疗具有进展表型的慢性纤维化间质性肺病, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=1f7f18966870)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2055013, encodeId=4ae4205501317, content=<a href='/topic/show?id=4623e7235f9' target=_blank style='color:#2F92EE;'>#纤维化间质性肺病#</a>, objectTitle=勃林格殷格翰的多途径激酶抑制剂Ofev治疗慢性纤维化间质性肺病，获得FDA的突破性治疗指定, objectType=article, longId=181137, objectId=82d718113e9c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=82d718113e9c, replyNumber=0, likeNumber=76, createdTime=2020-02-04, rootId=0, userName=654699882_84926986, userId=85df2500173, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=82d718113e9c, moduleTitle=勃林格殷格翰的多途径激酶抑制剂Ofev治疗慢性纤维化间质性肺病，获得FDA的突破性治疗指定, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=82d718113e9c)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

纤维化间质性肺病

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#纤维化间质性肺病#

European Radiology：CT定量在进行性纤维化间质性肺病中的价值

2024-08-06发表于上海

654699882_84926986 (审核中...)

前往app查看评论内容

#纤维化间质性肺病#

晚期肺结节病患者进行性纤维化间质性肺病表型的特征

2023-06-10

654699882_84926986 (审核中...)

前往app查看评论内容

#纤维化间质性肺病#

Front Med：进行性纤维化间质性肺病 (PF-ILD) 的管理

2022-06-07

654699882_84926986 (审核中...)

前往app查看评论内容

#纤维化间质性肺病#

Chest：纤维化间质性肺病患者体重指数和体重变化与死亡率之间的相关性

2022-10-27

654699882_84926986 (审核中...)

前往app查看评论内容

#纤维化间质性肺病#

2019年ERS：Nintedanib减慢纤维化间质性肺病的进展

2020-03-31

654699882_84926986 (审核中...)

前往app查看评论内容

#纤维化间质性肺病#

FDA扩展了勃林格殷格翰的尼达尼布的适应症，用于治疗具有进展表型的慢性纤维化间质性肺病

2020-10-08

654699882_84926986 (审核中...)

前往app查看评论内容

#纤维化间质性肺病#

勃林格殷格翰的多途径激酶抑制剂Ofev治疗慢性纤维化间质性肺病，获得FDA的突破性治疗指定

2020-02-04

科室
- - 订阅+
  - 更多科室
工具
服务